B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Sandwich' strategy aims to stop leukemia relapse after CAR t therapy
Disease control OngoingThis phase 2 trial tests a combination of two types of CAR T-cells (targeting CD22 and CD19) followed by a stem cell transplant using the patient's own cells, then more CAR T-cells—a 'sandwich' approach—to prevent relapse in B-cell acute lymphoblastic leukemia. The study includes…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 23, 2026 20:32 UTC
-
Engineered immune cells take on stubborn leukemia
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
Gentler chemo combo shows promise for older leukemia patients
Disease control OngoingThis phase 2 trial is testing a drug called blinatumomab, given as a shot under the skin, together with a milder chemotherapy regimen for people aged 60 and older (or younger adults who are too frail for standard chemo) with a type of blood cancer called B-cell acute lymphoblasti…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse after CAR-T therapy
Disease control TerminatedThis study tests a new treatment plan for young adults and adults with B-cell acute lymphoblastic leukemia. The approach uses a combination of immunotherapies before and after a stem cell transplant, including a 'sandwich' of two types of CAR-T cells. The goal is to reduce the ri…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Can a cancer pill boost CAR T-Cell power against leukemia?
Disease control OngoingThis early-phase study tests whether adding pulses of the cancer drug dasatinib can improve CAR T-cell therapy (brexucabtagene autoleucel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants will receive dasatinib on a weekly 3-day sched…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma
Disease control OngoingThis study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatm…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
Engineered immune cells take on stubborn leukemia in early trial
Disease control OngoingThis early-phase study tests a new way to fight acute lymphoblastic leukemia (ALL) that has not responded to standard chemotherapy. Researchers take a patient's own immune cells, modify them to recognize and attack cancer cells, and infuse them back. The goal is to see if this ap…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Real-World data shows promise for CNCT-19 in tough leukemia
Disease control OngoingThis study looks at how well a treatment called CNCT-19 works for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). Researchers will review medical records from 275 patients across multiple hospitals in China to see how many achieve remission an…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New cell therapy aims to wipe out stubborn leukemia in kids
Disease control OngoingThis study tests a treatment called tisagenlecleucel (a type of CAR-T cell therapy) in children and young adults aged 1 to 25 with high-risk B-cell acute lymphoblastic leukemia. Participants have cancer cells still present after initial chemotherapy. The treatment uses the patien…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New combo therapy aims to boost leukemia fight without harming transplant
Disease control OngoingThis early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) after a stem cell transplant is safe for adults with a high-risk type of B-cell leukemia. About 22 participants will receive the treatment to see if it can help prevent the cancer fr…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. NKX019 uses donor immune cells (natural killer cells) that are specially designed to fin…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New drug combo shows promise in early trial for tough blood cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
Boosting CAR t: early second dose may keep childhood leukemia at bay
Disease control OngoingThis study tests whether giving a second dose of the CAR T-cell therapy tisagenlecleucel early can keep the immune system's B cells low for at least 6 months in children and young adults with relapsed B-cell acute lymphoblastic leukemia. The goal is to reduce the chance of the ca…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC